Canonico S, Sciaudone G, Pacifico F, Santoriello A
Institute of General Surgery, School of Medicine, Second University of Naples, Italy.
Surgery. 1999 Mar;125(3):315-7.
Our purpose was to establish the efficacy of human fibrin glue (HFG) in preventing coagulative complications after inguinal hernia repair in patients with coagulation disorders.
A randomized controlled trial of 50 patients with coagulation disorders undergoing hernia repair was performed. Patients had concurrent coagulopathies as a consequence of liver disease or long-term treatment with anticoagulants. Coagulopathies were defined according to the following criteria: prothrombin time < 10.5 seconds, activated partial thromboplastin time < 21 seconds, and fibrinogen < 230 mg/dL. Patients were randomized in a 1:1 ratio with (group A) or without (control group B) use of HFG.
Postoperative hemorrhagic complications were significantly reduced in group A (4%) compared with group B (24%).
This study shows that HFG is effective in preventing local hemorrhagic complications after herniorrhaphy in patients with concurrent coagulation disorders. This implies that the use of HFG reduces the costs of prolonged hospitalization related to such complications.
我们的目的是确定人纤维蛋白胶（HFG）在预防凝血功能障碍患者腹股沟疝修补术后凝血并发症方面的疗效。
对50例接受疝修补术的凝血功能障碍患者进行了一项随机对照试验。患者因肝病或长期使用抗凝剂而并发凝血功能障碍。凝血功能障碍根据以下标准定义：凝血酶原时间<10.5秒，活化部分凝血活酶时间<21秒，纤维蛋白原<230mg/dL。患者按1:1比例随机分为使用HFG的A组和不使用HFG的对照组B。
与B组（24%）相比，A组（4%）术后出血并发症显著减少。
本研究表明，HFG在预防并发凝血功能障碍患者疝修补术后局部出血并发症方面有效。这意味着使用HFG可降低与此类并发症相关的延长住院时间的成本。
